Factor IX Polyklonale Antilichaam, AbBy FluorTM 488 Vervoeging

Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin, and factors X, IX, V, and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble fibrin clots and the promotion of platelet aggregation (1-3) . Coagulation factor IX (plasma thromboplastic component, F9, F.IX, HEMB) is a vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor (3,4) . Factor XIa mediated proteolytic cleavage of factor IX generates factor IXa, an active serine protease composed of a 145 amino acid light chain and a 236 amino acid catalytic heavy chain, linked through disulfide bonds (5) . Genetic alterations at the Factor IX locus such as point mutations, insertions and deletions, can lead to hemophilia B, also known as Christmas disease (6) .

Christmas Disease; Christmas factor; Coagulant factor IX; Coagulation factor 9; Coagulation factor IX plasma thromboplastic component; Coagulation factor IX; Coagulation factor IXa heavy chain; F9; FA9_HUMAN; Factor 9; Factor IX Deficiency; Factor9; FactorIX; FIX; GLA domain; Haemophilia B; MGC129641; MGC129642; P19 antibody Plasma thromboplastic component; Plasma thromboplastin component; PTC; Truncated coagulation factor IX.

2158

Human, Mouse, Rat

381-461/461

Factor IX

AbBy Fluor™ 488

KLH conjugated synthetic peptide derived from human Coagulation factor IXa heavy chain

WB, IF

Purified by Protein A.

499nm/519nm

1µg/µl

WB (1:300-5000), IF ()

Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

2158